Clovis Oncology, Inc. (CLVS) Stock Analysis
DELISTED 2022
What happened to Clovis Oncology, Inc. (CLVS) stock?
Clovis Oncology, Inc. (CLVS) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clovis Oncology, Inc. (CLVS) trades at $0.0812. Clovis Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing anti-cancer agents. The company filed for Chapter 11 reorganization in December 2022. Sector: Healthcare.
Last analyzed: May 9, 2026Analyst Coverage for CLVS: CLVS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLVS against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
CLVS: 1/2 scored disciplines lean bearish. Dominant signal: Moon AI bullish.
How is this calculated? →Clovis Oncology, Inc. (CLVS) Healthcare & Pipeline Overview
Clovis Oncology, Inc. is a biopharmaceutical company specializing in anti-cancer agents, including Rubraca for ovarian and prostate cancer. Facing financial challenges, the company filed for Chapter 11 reorganization in 2022, impacting its operations and future development of investigational therapies like lucitanib and FAP-2286 in a competitive market.
What Is the Investment Thesis for CLVS?
Clovis Oncology's investment thesis is complex due to its Chapter 11 reorganization filing in December 2022. The company's primary asset is Rubraca, which generates revenue from ovarian and prostate cancer treatments. However, the company's negative profit margin of -177.8% indicates significant financial challenges. Growth catalysts include potential successful restructuring and continued commercialization of Rubraca in existing markets. The development and potential approval of lucitanib and FAP-2286 represent long-term value drivers. Key risks include the uncertainties associated with the bankruptcy process, competition from other PARP inhibitors, and the company's ability to secure additional funding for research and development. The low beta of 0.22 suggests relatively low volatility compared to the market.
Based on FMP financials and quantitative analysis
CLVS Key Highlights
Rubraca is approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the United States and Europe, providing a revenue stream.
- Rubraca is also approved for metastatic castration-resistant prostate cancer in the United States, expanding its market reach.
- The company is developing lucitanib, an investigational angiogenesis inhibitor, potentially expanding its oncology pipeline.
- FAP-2286, an investigational peptide-targeted radionuclide therapy, represents a novel approach to cancer treatment.
- Clovis Oncology filed for Chapter 11 reorganization on December 11, 2022, impacting its financial stability and future operations.
Who Are CLVS's Competitors?
CLVS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AZN AstraZeneca PLC | $164.49 | -0.28% | $255B | 61 |
| GSK GSK plc | $51.96 | -1.74% | $104B | 61 |
| PFE Pfizer Inc. | $28.24 | +3.63% | $161B | 67 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $242.61 | +6.12% | $32.5B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLVS's Key Strengths?
Approved product (Rubraca) generating revenue.
- Pipeline of investigational therapies (lucitanib, FAP-2286).
- Strategic collaborations with established pharmaceutical companies.
- Experienced management team with expertise in oncology drug development.
What Are CLVS's Weaknesses?
Chapter 11 bankruptcy filing indicating financial distress.
- Negative profit margin (-177.8%) reflecting high operating expenses.
- Reliance on a single approved product (Rubraca) for revenue.
- Intense competition from other PARP inhibitors.
What Could Drive CLVS Stock Higher?
Restructuring efforts to emerge from Chapter 11 bankruptcy.
- Potential clinical trial results for lucitanib and FAP-2286.
- Regulatory decisions regarding potential label expansions for Rubraca.
- Continued commercialization of Rubraca in existing markets.
What Are the Key Risks for CLVS?
Uncertainties associated with the Chapter 11 bankruptcy process.
- Competition from other PARP inhibitors and emerging cancer therapies.
- Regulatory hurdles and potential delays in drug approvals.
- Dependence on external funding for research and development.
- Failure to successfully restructure the company and emerge from bankruptcy.
What Are the Growth Opportunities for CLVS?
- Expansion of Rubraca's Label: Clovis Oncology has the opportunity to expand Rubraca's label to include first-line maintenance therapy for ovarian cancer. This would significantly increase the addressable patient population and drive revenue growth. The market for first-line maintenance therapy in ovarian cancer is estimated to be substantial, with potential for multi-billion dollar sales. This expansion depends on positive clinical trial results and regulatory approvals, with a potential timeline of 2-3 years.
- Development of Lucitanib: Lucitanib, an investigational angiogenesis inhibitor, represents a significant growth opportunity for Clovis Oncology. Angiogenesis inhibitors are used in the treatment of various cancers, and lucitanib's unique target profile (VEGFR 1-3, PDGFRa/ß, and FGFR 1-3) could provide a competitive advantage. Successful clinical trials and regulatory approval could lead to a new revenue stream. The timeline for potential approval is estimated at 3-5 years, pending clinical trial progress.
- Advancement of FAP-2286: FAP-2286, an investigational peptide-targeted radionuclide therapy, offers a novel approach to cancer treatment by targeting fibroblast activation protein (FAP). This therapy has the potential to be used in a wide range of solid tumors. The market for targeted radionuclide therapies is growing, driven by the increasing demand for personalized medicine. Clinical trials are ongoing, and potential approval could occur in 4-6 years, contingent on positive results and regulatory review.
- Strategic Partnerships: Clovis Oncology can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its pipeline products. These partnerships can provide access to additional funding, expertise, and marketing resources. Collaborations with companies like Bristol Myers Squibb Company demonstrate the potential for such partnerships. The timeline for establishing new partnerships is variable, depending on the specific opportunities and negotiations.
- Geographic Expansion: Clovis Oncology has the opportunity to expand its commercial operations into new geographic markets. While Rubraca is currently approved in the United States and Europe, there is potential to launch the product in other regions, such as Asia and Latin America. This expansion would require regulatory approvals and the establishment of distribution networks. The timeline for geographic expansion is estimated at 2-4 years, depending on the specific market and regulatory requirements.
What Are CLVS's Competitive Advantages?
- Proprietary Drug Formulations: Clovis Oncology holds patents and proprietary formulations for Rubraca and its other drug candidates, providing a degree of market exclusivity.
- Regulatory Approvals: Obtaining regulatory approvals for its therapies creates a barrier to entry for competitors.
- Strategic Partnerships: Collaborations with companies like Pfizer and AstraZeneca provide access to resources and expertise, strengthening its competitive position.
- Specialty Distribution Network: The company's established network of specialty distributors and pharmacies facilitates the efficient delivery of its products to patients.
What Does CLVS Do?
Clovis Oncology, Inc., founded in 2009 and headquartered in Boulder, Colorado, is a biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative anti-cancer agents. The company's primary focus is on addressing significant unmet needs in cancer treatment. Its key product is Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP). Rubraca is approved in the United States and Europe for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. In the U.S., it is also approved for metastatic castration-resistant prostate cancer. Beyond Rubraca, Clovis Oncology has been developing lucitanib, an investigational angiogenesis inhibitor targeting vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFRa/ß), and fibroblast growth factor receptors (FGFR 1-3). Additionally, the company is working on FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP). Clovis Oncology distributes Rubraca through a network of specialty distributors and pharmacies. The company has established strategic collaborations and license agreements with various entities, including Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, 3B Pharmaceuticals GmbH, Bristol Myers Squibb Company, and Foundation Medicine, Inc. On December 11, 2022, Clovis Oncology, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
What Products and Services Does CLVS Offer?
- Develop and commercialize anti-cancer agents.
- Offer Rubraca (rucaparib) for recurrent ovarian, fallopian tube, and primary peritoneal cancer.
- Offer Rubraca for metastatic castration-resistant prostate cancer in the U.S.
- Develop lucitanib, an investigational angiogenesis inhibitor.
- Develop FAP-2286, an investigational peptide-targeted radionuclide therapy.
- Sell Rubraca through specialty distributors and pharmacies.
How Does CLVS Make Money?
- Develop and acquire anti-cancer drug candidates.
- Conduct clinical trials to demonstrate safety and efficacy.
- Obtain regulatory approvals from agencies like the FDA and EMA.
- Manufacture and market approved drugs, primarily through specialty distributors and pharmacies.
- Generate revenue through sales of Rubraca and potentially other approved therapies.
What Industry Does CLVS Operate In?
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Clovis Oncology operates in the oncology segment, which is driven by the increasing prevalence of cancer and the demand for innovative therapies. The market for PARP inhibitors, such as Rubraca, is competitive, with established players like AstraZeneca and GlaxoSmithKline. The company's Chapter 11 filing reflects the financial challenges faced by many biotechnology companies in bringing novel therapies to market. The success of Clovis Oncology depends on its ability to navigate the bankruptcy process, secure funding, and successfully commercialize its pipeline products.
Who Are CLVS's Key Customers?
- Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Patients with metastatic castration-resistant prostate cancer in the U.S.
- Healthcare providers who prescribe and administer Clovis Oncology's therapies.
- Specialty distributors and pharmacies that dispense Rubraca to patients.
- Hospitals and cancer centers that utilize Clovis Oncology's products.
Company Profile
Clovis Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Patrick Mahaffy. CLVS has traded publicly since 2011.
Key Financial Metrics
Return on equity for Clovis Oncology, Inc. stands at 120.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -55.9%, showing how much profit it generates from its asset base. A current ratio of 1.58 indicates the company holds enough short-term assets to cover its near-term obligations.
CLVS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Approved product (Rubraca) generating revenue.
- Pipeline of investigational therapies (lucitanib, FAP-2286).
- Strategic collaborations with established pharmaceutical companies.
- Experienced management team with expertise in oncology drug development.
Bear Case
- Chapter 11 bankruptcy filing indicating financial distress.
- Negative profit margin (-177.8%) reflecting high operating expenses.
- Reliance on a single approved product (Rubraca) for revenue.
- Intense competition from other PARP inhibitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CLVS Latest News
No recent news available for CLVS.
Leadership: Patrick Mahaffy
CEO
Patrick Mahaffy has served as the CEO of Clovis Oncology, Inc. He has extensive experience in the biopharmaceutical industry, with a focus on oncology drug development and commercialization. Prior to joining Clovis Oncology, Mr. Mahaffy held leadership positions at several other biotechnology companies. His background includes expertise in corporate strategy, business development, and financial management. He is responsible for overseeing the company's overall operations and strategic direction.
Track Record: Under Patrick Mahaffy's leadership, Clovis Oncology has achieved several key milestones, including the approval and commercialization of Rubraca. He has also overseen the development of the company's pipeline of investigational therapies, including lucitanib and FAP-2286. However, the company's recent Chapter 11 filing presents a significant challenge to his leadership. His ability to navigate the bankruptcy process and restructure the company will be critical to its future success.
Common Questions About CLVS (Healthcare)
What happened to Clovis Oncology, Inc. (CLVS) stock?
Clovis Oncology, Inc. (CLVS) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
Can I still buy CLVS shares?
No. CLVS stopped trading on public markets in December 2022, so the shares are not available through a broker. Anything you see quoted for CLVS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CLVS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Clovis Oncology, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Clovis Oncology, Inc. do?
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing anti-cancer agents. Its primary product is Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) approved for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as metastatic castration-resistant prostate cancer in the U.S.
What do analysts say about CLVS stock?
Given Clovis Oncology's Chapter 11 bankruptcy filing, analyst coverage and recommendations are likely limited and highly speculative. Key valuation metrics are difficult to assess due to the company's financial distress. Growth considerations depend on the company's ability to successfully restructure and continue commercializing Rubraca, as well as the potential for future approvals of its pipeline products.
What are the main risks for CLVS?
The main risks for Clovis Oncology include the uncertainties associated with its Chapter 11 bankruptcy process, competition from other PARP inhibitors and emerging cancer therapies, regulatory hurdles and potential delays in drug approvals, and dependence on external funding for research and development. The company's financial distress and negative profit margin also pose significant challenges.
How does Clovis Oncology, Inc. generate revenue in the healthcare sector?
Clovis Oncology, Inc. generates revenue primarily through the sales of Rubraca (rucaparib), its approved therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, and metastatic castration-resistant prostate cancer in the U.S. The company sells Rubraca through a network of specialty distributors and pharmacies, who then distribute the drug to patients and healthcare providers.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company's Chapter 11 bankruptcy filing introduces significant uncertainties.